THE TECHNOLOGY

Challenges

MRG therapeutics are believed to represent a paradigm shift in regenerative medicine and patient care. It has long been recognised that a stem cells ability to self-renew and their capacity for differentiation offers significant potential for the generation and repair of tissues. However, there were four significant challenges.

  • The first recognised challenge the Micregen researchers faced when considering stem cell treatment was to understand the mechanisms by which stem cells function in the injured microenvironment. The team identified these mechanisms and are now translating their preclinical results and findings to human studies
  • The second challenge to overcome, was to identify, harness the production of, and isolate the key differentiation factors that Secretomix use to induce repair and regeneration
  • The next significant challenge is avoiding immune rejection. MRG therapeutics have the potential to avoid immunological rejection because they derive from developmentally naïve stem cells, whilst also bypassing the need for whole cell transplant, thus creating a treatment that is allogenic (can be used by everyone) rather than an autologous treatment (only used by the donor). This means that MRG therapeutics  can be administered immediately at point of care and that recipients do not have to take immunosuppressive drugs to reduce the chances of rejection
  • The final challenge was the ability to scale-up the production of the Secretomix therapeutic by producing an immortalised, allogeneic and proprietary cell line.

Micregen’s intellectual property is being developed to deliver protected production processes that overcomes these challenges.

Secretomix®

Whole stem cell therapies have shown significant benefit over many years, across a wide range of disease and illness. Research shows that despite the observed benefits of the whole cell-based treatments, the proportion of cells that engraft into damaged tissue (the expected mechanism of action) is dramatically lower than the number of whole stem cells introduced. In fact, many of the beneficial effects were discovered to come from the paracrine acting secretions of the introduced whole stem cells.

Whole stem cell therapies have shown significant benefit over many years, across a wide range of disease and illness. Research shows that despite the observed benefits of the whole cell-based treatments, the proportion of cells that engraft into damaged tissue (the expected mechanism of action) is dramatically lower than the number of whole stem cells introduced. In fact, many of the beneficial effects were discovered to come from the paracrine acting secretions of the introduced whole stem cells.

Secretomix facilitate cell repair, reduce inflammation, reduce scarring, improve blood flow and generate a pro-regenerative microenvironment across a wide range of organs and tissue types. Micregen believe that their innovative approach has the potential to change the way that multiple critical and chronic problems are managed. Secretomix are cell-free biologics of stem cell origin.

Micregen’s Intellectual Property revolves around the development, optimisation, and manufacture of Micregen’s stem cell-derived, cell-free secretome therapeutics (“MRG Therapeutics”). These form the platform and are the basis for the development of therapeutics that accelerate regeneration and repair. The overarching goal and aim is to substantially improve patients’ health and wellbeing.

MRG Therapeutics

Micregen's therapeutics activate resident stem cells to repair damaged cells, reduce inflammation and scarring, improve blood flow and generate a pro-regenerative microenvironment across a wide range of organs.

Secretomix are a cell free approach, this reduces tumour risk or the inappropriate development of the wrong tissue type. These discoveries will enable Micregen to overcome significant barriers to translate stem cell technology into all areas of clinical medicine.

Micregen's therapeutics activate resident stem cells to repair damaged cells, reduce inflammation and scarring, improve blood flow and generate a pro-regenerative microenvironment across a wide range of organs.

Secretomix are a cell free approach, this reduces tumour risk or the inappropriate development of the wrong tissue type. These discoveries will enable Micregen to overcome significant barriers to translate stem cell technology into all areas of clinical medicine.

Furthermore, they harness the body's natural healing process and gain many of the clinical benefits whilst reducing the associated risks of conventional pharmaceuticals of overdose and contra-indication (major complications and even fatality if taken with certain other medicines) which is particularly relevant to an ageing population who take multiple prescriptions.

Since 2019 there has been an exponential growth in peer reviewed, published, scientific papers confirming Micregen’s approach, (600+ papers published in 2019 alone).

MRG1061

MRG1061 is Micregen’s first product and aims to target neonatal conditions. It is a multipotent, immortalised, stem cell-derived, cell-free injectable, designed to aid tissue regeneration.

The first clinical target is necrotising enterocolitis, an often-fatal condition in premature & new-born babies where portions of the bowel undergo wide-spread necrosis (tissue death).

MRG1161

MRG1161 is Micregen’s second product. MRG1161 is a pluripotent, allogeneic, stem cell-derived cell-free injectable designed to alleviate problems associated with ageing.

The first clinical target is disuse associated muscle atrophy and frailty. It is recognised that even after short period of inactivity (a short hospital stay or a week ‘off your feet’) has a serious and very detrimental effect in the older population’s ability to remain active and resume everyday tasks. Studies have shown that a week of inactivity in the over 60’s can result in a loss of muscle mass of up to 60%.

Micregen believe that MRG1161 has the potential to provide an important partial solution to this problem, allowing people to lead healthier, more active lives (increasing health-span) thereby dramatically improving quality of life.

MRG1061

MRG1061 is Micregen’s first product and aims to target neonatal conditions. It is a multipotent, immortalised, stem cell-derived, cell-free injectable, designed to aid tissue regeneration.

The first clinical target is necrotising enterocolitis, an often-fatal condition in premature & new-born babies where portions of the bowel undergo wide-spread necrosis (tissue death).

MRG1161

MRG1161 is Micregen’s second product. MRG1161 is a pluripotent, allogeneic, stem cell-derived cell-free injectable designed to alleviate problems associated with ageing.

The first clinical target is disuse associated muscle atrophy and frailty. It is recognised that even after short period of inactivity (a short hospital stay or a week ‘off your feet’) has a serious and very detrimental effect in the older population’s ability to remain active and resume everyday tasks. Studies have shown that a week of inactivity in the over 60’s can result in a loss of muscle mass of up to 60%.

Micregen believe that MRG1161 has the potential to provide an important partial solution to this problem, allowing people to lead healthier, more active lives (increasing health-span) thereby dramatically improving quality of life.

WHAT WE DO

  1. THE SCIENCE
  2. THE TECHNOLOGY
  3. NEONATAL DISEASE
  4. AGE-ASSOCIATED CONDITIONS